Cargando…

High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study

Gastric cancer (GC) is a heterogeneous disease. This heterogeneity applies not only to morphological and phenotypic features but also to geographical variations in incidence and mortality rates. As Chile has one of the highest mortality rates within South America, we sought to define a molecular pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Cordova-Delgado, Miguel, Pinto, Mauricio P., Retamal, Ignacio N., Muñoz-Medel, Matías, Bravo, María Loreto, Fernández, María F., Cisternas, Betzabé, Mondaca, Sebastián, Sanchez, César, Galindo, Hector, Nervi, Bruno, Ibáñez, Carolina, Acevedo, Francisco, Madrid, Jorge, Peña, José, Koch, Erica, Maturana, Maria José, Romero, Diego, de la Jara, Nathaly, Torres, Javiera, Espinoza, Manuel, Balmaceda, Carlos, Liao, Yuwei, Li, Zhiguang, Freire, Matías, Gárate-Calderón, Valentina, Cáceres, Javier, Sepúlveda-Hermosilla, Gonzalo, Lizana, Rodrigo, Ramos, Liliana, Artigas, Rocío, Norero, Enrique, Crovari, Fernando, Armisén, Ricardo, Corvalán, Alejandro H., Owen, Gareth I., Garrido, Marcelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770659/
https://www.ncbi.nlm.nih.gov/pubmed/31480291
http://dx.doi.org/10.3390/cancers11091275
_version_ 1783455527664091136
author Cordova-Delgado, Miguel
Pinto, Mauricio P.
Retamal, Ignacio N.
Muñoz-Medel, Matías
Bravo, María Loreto
Fernández, María F.
Cisternas, Betzabé
Mondaca, Sebastián
Sanchez, César
Galindo, Hector
Nervi, Bruno
Ibáñez, Carolina
Acevedo, Francisco
Madrid, Jorge
Peña, José
Koch, Erica
Maturana, Maria José
Romero, Diego
de la Jara, Nathaly
Torres, Javiera
Espinoza, Manuel
Balmaceda, Carlos
Liao, Yuwei
Li, Zhiguang
Freire, Matías
Gárate-Calderón, Valentina
Cáceres, Javier
Sepúlveda-Hermosilla, Gonzalo
Lizana, Rodrigo
Ramos, Liliana
Artigas, Rocío
Norero, Enrique
Crovari, Fernando
Armisén, Ricardo
Corvalán, Alejandro H.
Owen, Gareth I.
Garrido, Marcelo
author_facet Cordova-Delgado, Miguel
Pinto, Mauricio P.
Retamal, Ignacio N.
Muñoz-Medel, Matías
Bravo, María Loreto
Fernández, María F.
Cisternas, Betzabé
Mondaca, Sebastián
Sanchez, César
Galindo, Hector
Nervi, Bruno
Ibáñez, Carolina
Acevedo, Francisco
Madrid, Jorge
Peña, José
Koch, Erica
Maturana, Maria José
Romero, Diego
de la Jara, Nathaly
Torres, Javiera
Espinoza, Manuel
Balmaceda, Carlos
Liao, Yuwei
Li, Zhiguang
Freire, Matías
Gárate-Calderón, Valentina
Cáceres, Javier
Sepúlveda-Hermosilla, Gonzalo
Lizana, Rodrigo
Ramos, Liliana
Artigas, Rocío
Norero, Enrique
Crovari, Fernando
Armisén, Ricardo
Corvalán, Alejandro H.
Owen, Gareth I.
Garrido, Marcelo
author_sort Cordova-Delgado, Miguel
collection PubMed
description Gastric cancer (GC) is a heterogeneous disease. This heterogeneity applies not only to morphological and phenotypic features but also to geographical variations in incidence and mortality rates. As Chile has one of the highest mortality rates within South America, we sought to define a molecular profile of Chilean GCs (ClinicalTrials.gov identifier: NCT03158571/(FORCE1)). Solid tumor samples and clinical data were obtained from 224 patients, with subsets analyzed by tissue microarray (TMA; n = 90) and next generation sequencing (NGS; n = 101). Most demographic and clinical data were in line with previous reports. TMA data indicated that 60% of patients displayed potentially actionable alterations. Furthermore, 20.5% were categorized as having a high tumor mutational burden, and 13% possessed micro-satellite instability (MSI). Results also confirmed previous studies reporting high Epstein-Barr virus (EBV) positivity (13%) in Chilean-derived GC samples suggesting a high proportion of patients could benefit from immunotherapy. As expected, TP53 and PIK3CA were the most frequently altered genes. However, NGS demonstrated the presence of TP53, NRAS, and BRAF variants previously unreported in current GC databases. Finally, using the Kendall method, we report a significant correlation between EBV+ status and programmed death ligand-1 (PDL1)+ and an inverse correlation between p53 mutational status and MSI. Our results suggest that in this Chilean cohort, a high proportion of patients are potential candidates for immunotherapy treatment. To the best of our knowledge, this study is the first in South America to assess the prevalence of actionable targets and to examine a molecular profile of GC patients.
format Online
Article
Text
id pubmed-6770659
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-67706592019-10-30 High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study Cordova-Delgado, Miguel Pinto, Mauricio P. Retamal, Ignacio N. Muñoz-Medel, Matías Bravo, María Loreto Fernández, María F. Cisternas, Betzabé Mondaca, Sebastián Sanchez, César Galindo, Hector Nervi, Bruno Ibáñez, Carolina Acevedo, Francisco Madrid, Jorge Peña, José Koch, Erica Maturana, Maria José Romero, Diego de la Jara, Nathaly Torres, Javiera Espinoza, Manuel Balmaceda, Carlos Liao, Yuwei Li, Zhiguang Freire, Matías Gárate-Calderón, Valentina Cáceres, Javier Sepúlveda-Hermosilla, Gonzalo Lizana, Rodrigo Ramos, Liliana Artigas, Rocío Norero, Enrique Crovari, Fernando Armisén, Ricardo Corvalán, Alejandro H. Owen, Gareth I. Garrido, Marcelo Cancers (Basel) Article Gastric cancer (GC) is a heterogeneous disease. This heterogeneity applies not only to morphological and phenotypic features but also to geographical variations in incidence and mortality rates. As Chile has one of the highest mortality rates within South America, we sought to define a molecular profile of Chilean GCs (ClinicalTrials.gov identifier: NCT03158571/(FORCE1)). Solid tumor samples and clinical data were obtained from 224 patients, with subsets analyzed by tissue microarray (TMA; n = 90) and next generation sequencing (NGS; n = 101). Most demographic and clinical data were in line with previous reports. TMA data indicated that 60% of patients displayed potentially actionable alterations. Furthermore, 20.5% were categorized as having a high tumor mutational burden, and 13% possessed micro-satellite instability (MSI). Results also confirmed previous studies reporting high Epstein-Barr virus (EBV) positivity (13%) in Chilean-derived GC samples suggesting a high proportion of patients could benefit from immunotherapy. As expected, TP53 and PIK3CA were the most frequently altered genes. However, NGS demonstrated the presence of TP53, NRAS, and BRAF variants previously unreported in current GC databases. Finally, using the Kendall method, we report a significant correlation between EBV+ status and programmed death ligand-1 (PDL1)+ and an inverse correlation between p53 mutational status and MSI. Our results suggest that in this Chilean cohort, a high proportion of patients are potential candidates for immunotherapy treatment. To the best of our knowledge, this study is the first in South America to assess the prevalence of actionable targets and to examine a molecular profile of GC patients. MDPI 2019-08-30 /pmc/articles/PMC6770659/ /pubmed/31480291 http://dx.doi.org/10.3390/cancers11091275 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Cordova-Delgado, Miguel
Pinto, Mauricio P.
Retamal, Ignacio N.
Muñoz-Medel, Matías
Bravo, María Loreto
Fernández, María F.
Cisternas, Betzabé
Mondaca, Sebastián
Sanchez, César
Galindo, Hector
Nervi, Bruno
Ibáñez, Carolina
Acevedo, Francisco
Madrid, Jorge
Peña, José
Koch, Erica
Maturana, Maria José
Romero, Diego
de la Jara, Nathaly
Torres, Javiera
Espinoza, Manuel
Balmaceda, Carlos
Liao, Yuwei
Li, Zhiguang
Freire, Matías
Gárate-Calderón, Valentina
Cáceres, Javier
Sepúlveda-Hermosilla, Gonzalo
Lizana, Rodrigo
Ramos, Liliana
Artigas, Rocío
Norero, Enrique
Crovari, Fernando
Armisén, Ricardo
Corvalán, Alejandro H.
Owen, Gareth I.
Garrido, Marcelo
High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study
title High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study
title_full High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study
title_fullStr High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study
title_full_unstemmed High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study
title_short High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study
title_sort high proportion of potential candidates for immunotherapy in a chilean cohort of gastric cancer patients: results of the force1 study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770659/
https://www.ncbi.nlm.nih.gov/pubmed/31480291
http://dx.doi.org/10.3390/cancers11091275
work_keys_str_mv AT cordovadelgadomiguel highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT pintomauriciop highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT retamalignacion highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT munozmedelmatias highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT bravomarialoreto highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT fernandezmariaf highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT cisternasbetzabe highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT mondacasebastian highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT sanchezcesar highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT galindohector highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT nervibruno highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT ibanezcarolina highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT acevedofrancisco highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT madridjorge highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT penajose highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT kocherica highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT maturanamariajose highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT romerodiego highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT delajaranathaly highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT torresjaviera highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT espinozamanuel highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT balmacedacarlos highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT liaoyuwei highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT lizhiguang highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT freirematias highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT garatecalderonvalentina highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT caceresjavier highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT sepulvedahermosillagonzalo highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT lizanarodrigo highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT ramosliliana highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT artigasrocio highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT noreroenrique highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT crovarifernando highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT armisenricardo highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT corvalanalejandroh highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT owengarethi highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study
AT garridomarcelo highproportionofpotentialcandidatesforimmunotherapyinachileancohortofgastriccancerpatientsresultsoftheforce1study